Increased platelet count is an indicator of metastasis in patients with nasopharyngeal carcinoma

Tumor Biology

Volumn 34, Issue 1, 2013, Pages 39-45

  Gao, Jin ^b   Zhang, Hong Yan ^b   Xia, Yun Fei ^a  

^a SUN YAT SEN UNIVERSITY   (China)

^b ANHUI PROVINCIAL HOSPITAL   (China)

Author keywords

Metastasis; Nasopharyngeal carcinoma; Platelet count; Survival; Thrombocytosis

Indexed keywords

ADOLESCENT; ADULT; AGED; CANCER ADJUVANT THERAPY; CANCER CHEMOTHERAPY; CANCER PROGNOSIS; CANCER RADIOTHERAPY; CANCER STAGING; CANCER SURVIVAL; CELL INTERACTION; CHILD; CLINICAL EVALUATION; CLINICAL FEATURE; COMPUTER ASSISTED RADIOTHERAPY; DIAGNOSTIC VALUE; DISEASE ASSOCIATION; DISEASE FREE SURVIVAL; DISEASE MARKER; FEMALE; HUMAN; INTENSITY MODULATED RADIATION THERAPY; LOCAL RECURRENCE FREE SURVIVAL; MAJOR CLINICAL STUDY; MALE; METASTASIS; METASTASIS FREE SURVIVAL; MOLECULAR MECHANICS; NASOPHARYNX CARCINOMA; PATHOLOGY; PRIORITY JOURNAL; RADIATION DOSE; RETROSPECTIVE STUDY; REVIEW; SCHOOL CHILD; SEX DIFFERENCE; SURVIVAL PREDICTION; THROMBOCYTE COUNT; THROMBOCYTOSIS; TREATMENT OUTCOME; TUMOR VOLUME;

EID: 84872791417     PISSN: 10104283     EISSN: 14230380     Source Type: Journal    
DOI: 10.1007/s13277-012-0508-y     Document Type: Review

References (25)

1. Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. CA Cancer J Clin. 2011;61(2):69-90. doi: 10.3322/caac.20107.
2. Lee AW, Tung SY, Ngan RK, Chappell R, Chua DT, Lu TX, et al. Factors contributing to the efficacy of concurrent-adjuvant chemotherapy for locoregionally advanced nasopharyngeal carcinoma: combined analyses of NPC-9901 and NPC-9902 Trials. Eur J Cancer. 2011;47(5):656-66. doi: 10.1016/j.ejca.2010. 10.026.
3. Kim YJ, Go H, Wu HG, Jeon YK, Park SW, Lee SH. Immunohistochemical study identifying prognostic biomolecular markers in nasopharyngeal carcinoma treated by radiotherapy. Head Neck. 2011;33(10):1458-66. doi: 10.1002/hed.21611.
4. Liao WT, Song LB, Zhang HZ, Zhang X, Zhang L, Liu WL, et al. Centromere protein H is a novel prognostic marker for nasopharyngeal carcinoma progression and overall patient survival. Clin Cancer Res. 2007;13(2 Pt 1):508-14. doi: 10.1158/1078-0432.CCR-06-1512.
5. Lee M, Kim SW, Nam EJ, Yim GW, Kim S, Kim YT. The impact of pretreatment thrombocytosis and persistent thrombocytosis after adjuvant chemotherapy in patients with advanced epithelial ovarian cancer. Gynecol Oncol. 2011;122(2):238-41. doi: 10.1016/j.ygyno.2011.04.012.
6. Seda CJ, Salas AS, Sanchez CG, Blasco JM, Garcia IO, Sanchez JM, et al. Thrombocytosis and hematocrit as prognostic factors in renal carcinoma. Arch Esp Urol. 2011;64(9):883-90.
7. Cho DS, Kim SJ, Lee SH, Ahn HS, Kim YS, Kim SI. Prognostic significance of preoperative C-reactive protein elevation and thrombocytosis in patients with non-metastatic renal cell carcinoma. Korean J Urol. 2011;52(2):104-9. doi: 10.4111/kju.2011.52.2.104.
8. Lin MS, Huang JX, Zhu J, Shen HZ. Elevation of platelet count in patients with colorectal cancer predicts tendency to metastases and poor prognosis. Hepatogastroenterology. 2012;59(118):1687-90. doi: 10.5754/hge12277.
9. Hwang SG, Kim KM, Cheong JH, Kim HI, An JY, Hyung WJ, et al. Impact of pretreatment thrombocytosis on blood-borne metastasis and prognosis of gastric cancer. Eur J Surg Oncol. 2012;38(7):562-7. doi: 10.1016/j.ejso.2012.04.009.
10. Gorelick C, Andikyan V, Mack M, Lee YC, Abulafia O. Prognostic significance of preoperative thrombocytosis in patients with endometrial carcinoma in an inner-city population. Int J Gynecol Cancer. 2009;19(8):1384-9. doi: 10.1111/IGC.0b013e3181a47d47.
11. Lu CC, Chang KW, Chou FC, Cheng CY, Liu CJ. Association of pretreatment thrombocytosis with disease progression and survival in oral squamous cell carcinoma. Oral Oncol. 2007;43(3):283-8. doi: 10.1016/j.oraloncology.2006.03. 010.
12. Greene F. AJCC cancer staging handbook: from the AJCC cancer staging manual. New York: Springer; 2002.
13. Gonzalez Barcala FJ, Garcia Prim JM, Moldes Rodriguez M, Alvarez Fernandez J, Rey Rey MJ, Pose Reino A, et al. Platelet count: association with prognosis in lung cancer. Med Oncol. 2010;27(2):357-62. doi: 10.1007/s12032-009-9217-9.
14. Buergy D, Wenz F, Groden C, Brockmann MA. Tumor-platelet interaction in solid tumors. Int J Cancer. 2012;130(12):2747-60. doi: 10.1002/ijc.27441.
15. Borsig L. The role of platelet activation in tumor metastasis. Expert Rev Anticancer Ther. 2008;8(8):1247-55. doi: 10.1586/14737140.8.8.1247.
16. Gerotziafas GT, Papageorgiou C, Hatmi M, Samama MM, Elalamy I. Clinical studies with anticoagulants to improve survival in cancer patients. Pathophysiol Haemost Thromb. 2008;36(3-4):204-11. doi: 10.1159/000175158.
17. Sierko E, Wojtukiewicz MZ. Platelets and angiogenesis in malignancy. Semin Thromb Hemost. 2004;30(1):95-108. doi: 10.1055/s-2004-822974.
18. Stone RL, Nick AM, McNeish IA, Balkwill F, Han HD, Bottsford-Miller J, et al. Paraneoplastic thrombocytosis in ovarian cancer. N Engl J Med. 2012;366(7):610-8. doi: 10.1056/NEJMoa1110352.
19. Erdemir F, Kilciler M, Bedir S, Ozgok Y, Coban H, Erten K. Clinical significance of platelet count in patients with renal cell carcinoma. Urol Int. 2007;79(2):111-6. doi: 10.1159/000106322.
20. Crasta JA, Premlatha TS, Krishnan SM, Vallikad E, Rameshkumar K. Significance of preoperative thrombocytosis in epithelial ovarian cancer. Indian J Pathol Microbiol. 2010;53(1):54-6. doi: 10.4103/0377-4929.59184.
21. Sasaki K, Kawai K, Tsuno NH, Sunami E, Kitayama J. Impact of preoperative thrombocytosis on the survival of patients with primary colorectal cancer. World J Surg. 2012;36(1):192-200. doi: 10.1007/s00268-011-1329-7.
22. Choe KS, Correa D, Jani AB, Liauw SL. The use of anticoagulants improves biochemical control of localized prostate cancer treated with radiotherapy. Cancer. 2010;116(7):1820-6. doi: 10.1002/cncr.24890.
23. Kuderer NM, Khorana AA, Lyman GH, Francis CW. A meta-analysis and systematic review of the efficacy and safety of anticoagulants as cancer treatment: impact on survival and bleeding complications. Cancer. 2007;110(5):1149-61. doi: 10.1002/cncr.22892.
24. Phillips PG, Yalcin M, Cui H, Abdel-Nabi H, Sajjad M, Bernacki R, et al. Increased tumor uptake of chemotherapeutics and improved chemoresponse by novel non-anticoagulant low molecular weight heparin. Anticancer Res. 2011;31(2):411-9.
25. van Doormaal FF, Di Nisio M, Otten HM, Richel DJ, Prins M, Buller HR. Randomized trial of the effect of the low molecular weight heparin nadroparin on survival in patients with cancer. J Clin Oncol. 2011;29(15):2071-6. doi: 10.1200/JCO.2010.31.9293.